IGEM Therapeutics

IGEM Therapeutics is a clinical-stage biotechnology company pioneering the development of Immunoglobulin E (IgE) antibodies for the treatment of cancer. By utilizing the unique properties of IgE, which has a significantly higher affinity for its receptors on immune cells compared to standard IgG antibodies, the company aims to trigger a more powerful and sustained immune attack against solid tumors. Their lead candidate, MOv18 IgE, is a first-in-class therapeutic targeting folate receptor alpha and is currently in Phase 1 clinical development for ovarian cancer. IGEM's pipeline also includes programs targeting HER2 and CSPG4, supported by a strong foundation of academic research from King's College London. The company is backed by leading life science investors and is headquartered in London, United Kingdom.